Published online Jan 14, 2021. doi: 10.3748/wjg.v27.i2.162
Peer-review started: September 23, 2020
First decision: November 8, 2020
Revised: November 11, 2020
Accepted: December 23, 2020
Article in press: December 23, 2020
Published online: January 14, 2021
Fucosylation is one of the most important glycosylation involved in cancer and inflammation. Recently, we have succeeded to establish a novel glycan antibody 10-7G mAb which directly recognizes fucosylated haptoglobin (Fuc-Hpt), and developed its enzyme-linked immunosorbent assay system.
Although fecal and serum biomarkers have been extremely important and supportive for monitoring of Inflammatory bowel disease (IBD), their low sensitivity and high variability characteristics limit clinical efficacy. Thus, the establishment of better biomarkers is expected.
This research aimed to investigate the usefulness of the serum levels of Fuc-Hpt (10-7G values) as a potential biomarker for monitoring disease activity in IBD.
Intestinal tissues of IBD patients were examined immunohistochemically using the 10-7G mAb. The 10-7G values were measured using serum from patients with IBD, acute enteritis (AE), and healthy volunteers. Correlation analysis and Receiver operating characteristic curve analysis were performed to evaluate the usefulness of the 10-7G values as a biomarker for IBD compared to conventional serum biomarkers and various clinical parameters.
Positive 10-7G mAb staining was observed in lymphocytes infiltrating into inflammatory sites of the mucosal layer. The 10-7G values were significantly higher in patients with IBD and AE. Statistical analyses showed that the 10-7G values could evaluate intestinal inflammation and endoscopic mucosal healing in ulcerative colitis (UC).
Fuc-Hpt is produced by lymphocytes infiltrating into sites of inflammation in the intestine and the serum 10-7G value is a non-invasive biomarker for evaluating endoscopic remission in UC.
Further studies are needed to fully elucidate the mechanism underlying the secretion of Fuc-Hpt by immune cells. In addition, we will measure serum 10-7G values of same patients with UC in follow-up study.